All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

DONATE

Brought to you by

Scientific Education Support logo

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

SubtypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2019-09-18T15:08:25.000Z

SOHO 2019 | What is in the pipeline for the treatment of T-cell lymphoma?

By Joanna Nikitorowicz-Buniak, Elina Simanovits, Owen O'Connor
Featured
Owen O'Connor
Sep 18, 2019
Share:

Bookmark this article

During SOHO 2019, Houston, US, the Lymphoma Hub asked Dr Owen A. O’Connor from Columbia University, New York, US, about treatments in the pipeline for T-cell lymphoma. He gives an update on the recent clinical developments for patients with relapsed or refractory diseases. He also describes treatment paradigms incorporating combinations of drugs with novel backbones, which hopefully in the future will replace CHOP-based therapies.

What is in the pipeline for the treatment of T-cell lymphoma?

More about...
Anaplastic large cell lymphomaAngioimmunoblastic T-cell lymphomaBrentuximab vedotinCHOPEpstein – Barr virus-positive T-cell lymphomaMature T and NK cell neoplasmsMycosis fungoidesPembrolizumabPeripheral T-cell lymphomaPralatrexateRomidepsinSOHO 2019Sézary syndromeT/NK-cell leukemia

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
60 votes - 49 days left ...

Related articles

Add bookmark

Alemtuzumab and CHOP for aggressive T-cell lymphoma

In this phase I, dose escalation trial, the authors investigated the possibility of combining CHOP chemotherapy with alemtuzumab, as a potential regimen against aggressive T-cell lymphoma.

Feb 25, 2019
Add bookmark

Alemtuzumab and CHOP for aggressive T-cell lymphoma

In this phase I, dose escalation trial, the authors investigated the possibility of combining CHOP chemotherapy with alemtuzumab, as a potential...

Feb 25, 2019
Add bookmark

Brentuximab vedotin plus chemotherapy for CD30+ PTCL: Results from the phase III ECHELON-2 trial

ECHELON-2 is a global, double-blind, active-comparator, randomized, phase III trial that investigated the efficacy and safety of brentuximab vedotin plus...

Jan 24, 2019
Add bookmark

Brentuximab vedotin plus chemotherapy for CD30+ PTCL: Results from the phase III ECHELON-2 trial

ECHELON-2 is a global, double-blind, active-comparator, randomized, phase III trial that investigated...

Jan 24, 2019

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox